Evidence map›Paper›PMID 41087560›Full record

ArticleMolecular psychiatry2026

GRIN2A null variants confer a high risk for early-onset schizophrenia and other mental disorders and potentially enable precision therapy.

Johannes R Lemke, Andrea Eoli, Ilona Krey, Bernt Popp, Vincent Strehlow, Dirk A Wittekind, Anna-Leena Vuorinen, Hesham M Aldhalaan, Sarah Baer, Anne de Saint Martin and 22 more

Erratum issuedAbstract read
In one paragraph

Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

32 authors.

Johannes R Lemke *Institute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany. johannes.lemke@medizin.uni-leipzig.de.ORCID 0000-0002-4435-6610
Andrea Eoli *Hasso Plattner Institute, Digital Engineering Faculty, University of Potsdam, Potsdam, Germany.
Ilona KreyInstitute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany.
Bernt PoppInstitute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany.
Vincent StrehlowInstitute of Human Genetics, University of Leipzig Medical Center, Leipzig, Germany.
Dirk A WittekindDepartment of Psychiatry and Psychotherapy, University of Leipzig Medical Center, Leipzig, Germany.
Anna-Leena VuorinenInstitute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-5658-1305
Hesham M AldhalaanDepartment of Neuroscience Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Kingdom of Saudi Arabia.
Sarah BaerDepartment of Pediatric Neurology, University Hospitals of Strasbourg, Strasbourg, France.
Anne de Saint MartinDepartment of Pediatric Neurology, University Hospitals of Strasbourg, Strasbourg, France.
Trine B HammerDepartment of Clinical Genetics, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.
Isabella HermanDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
Frauke HornemannDepartment of Pediatrics, Klinikum Chemnitz, Chemnitz, Germany.
Trine IngebrigtsenNational Centre for Epilepsy, Oslo University Hospital, Oslo, Norway.
Damien LedererCentre de Génétique Humaine, Institut de Pathologie et Génétique (IPG), Charleroi (Gosselies), Belgium.
Gaetan LescaDepartment of Medical Genetics, University Hospital of Lyon, Claude Bernard University Lyon 1, Lyon, France.ORCID 0000-0001-7691-9492
Dana MarafieDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
Mikael MathotNeuropediatric Unit, CHU UCL-Namur, Namur, Belgium.
Jill A RosenfeldDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
Rikke S MøllerDepartment of Epilepsy Genetics and Personalized Medicine, The Danish Epilepsy Centre, Dianalund, Denmark.ORCID 0000-0002-9664-1448
Helenius J SchelhaasDepartment of Neurology, Stichting Epilepsie Instellingen Nederland, SEIN, Zwolle, The Netherlands.
Chelsey StillmanSection of Child Neurology, Department of Pediatrics, University of Colorado, Aurora, CO, USA.
Alessandro OrsiniSection of Pediatric Neurology, Division of Pediatrics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Anup D PatelDivision of Pediatric Neurology, Nationwide Children's Hospital, Department of Pediatrics, The Ohio State College of Medicine, Columbus, OH, USA.
Juliette PiardCentre de Génétique Humaine, Centre Hospitalier Universitaire, Université de Franche-Comté, Besançon, France.ORCID 0000-0001-5244-5325
Pierangelo VeggiottiNeuroscience Research Center, Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.
Danique R M VlaskampDepartment of Genetics and Department of Neurology, University Medical Center Groningen, Groningen, The Netherlands.
Sarah WeckhuysenVIB-Center for Molecular Neurology, VIB, Antwerp, Belgium.ORCID 0000-0003-2878-1147
Stephen F TraynelisDepartment of Pharmacology and Chemical Biology, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0002-3750-9615
Tim A BenkeSection of Child Neurology, Department of Pediatrics, University of Colorado, Aurora, CO, USA.
Henrike O HeyneHasso Plattner Institute, Digital Engineering Faculty, University of Potsdam, Potsdam, Germany. Henrike.Heyne@hpi.de.
Steffen SyrbeHeidelberg University, Medical Faculty of Heidelberg, Center for Child and Adolescent Medicine, Clinic 1, Division of Pediatric Epileptology, Heidelberg, Germany.ORCID 0000-0003-2543-4844

Funding

Glutamate receptors and human neurological diseaseR35NS111619 · NINDS · EMORY UNIVERSITY · PI Stephen F Traynelis · 2019 to 2026
$6.6M
Deutsche Forschungsgemeinschaft (German Research Foundation) 516649954NINDS NIH HHS R35 NS111619Simons Foundation 732132U.S. Department of Health & Human Services | National Institutes of Health (NIH) NS111619
6 · The paper itself

Abstract

Rare genetic factors have been shown to substantially contribute to mental illness, but so far, no precision treatments for mental disorders have been described. It was recently identified that rare variants in GRIN2A encoding the GluN2A subunit of the N-methyl-D-aspartate receptor (NMDAR) confer a substantial risk for schizophrenia. To determine the prevalence of mental disorders among individuals with GRIN2A-related disorders, we enquired the presence of psychiatric symptoms in 235 individuals with pathogenic variants in GRIN2A who had previously enrolled in our global GRIN registry. We identified null variants in GRIN2A (GRIN2A

Indexed as

Mental DisordersReceptors, N-Methyl-D-AspartateSchizophreniaAdolescentAdultAge of OnsetChildCohort StudiesFemaleGenetic Predisposition to DiseaseHumansLongitudinal StudiesMaleMiddle AgedPhenotypePrecision MedicineReceptors, N-Methyl-D-Aspartate

Identifiers

PMID41087560
PMCPMC12700805

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.